EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People

Zinan Zhao, Yuxuan Zhao, Xiaowen Hu, Xue Wang, Gengchen Wang, Xinyi Zhang, Wenliang Dong, Luwen Shi, Xiaodong Guan iD, Christine Y Lu, Pengfei Jin, Xiaoyan Nie iD

Journal of the American Geriatrics Society · 2025-12 · 73 (12) · 3679-3689

DOI: 10.1111/jgs.70126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 29.09.2025. Verfasst von Zinan Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beiji…. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Pharmacogenetics, Practice Patterns, Physicians'. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacogenetic testing offers a pathway to safer prescribing and improved outcomes in older adults, who face heightened risks of adverse drug reactions due to polypharmacy and age‐related metabolic changes. This study evaluates the prevalence of actionable pharmacogenetic biomarker use and estimates the potential impact of genotype‐guided dosing in Chinese older adults.

Methods

This retrospective cross‐sectional analysis utilized 2015–2017 claims data from the China Health Insurance Research Association (CHIRA), encompassing 3,309,025 older patients (≥ 65 years) and 74,415,484 prescriptions. Drugs with Clinical Pharmacogenomics Implementation Consortium (CPIC) Level A evidence for actionable pharmacogenetic variants ( n = 53) were identified. Key measures included the prescribing prevalence of Level A drugs and projected rates of actionable phenotype‐driven dosing changes, calculated using population‐specific genotype frequencies from PharmGKB and published sources.

Results

Among older adults, 43.4% (433.8 per 1000) were prescribed ≥ 1 CPIC Level A drug. Atorvastatin (131.1 per 1000), omeprazole (124.3 per 1000), and clopidogrel (75.7 per 1000) were the most common. Over one‐third (36.5%; 365.3 per 1000) of exposures required genotype‐guided dose adjustments, with clopidogrel (CYP2C19) and statins (SLCO1B1) representing the highest‐priority gene‐drug interactions (259.6 and 221.8 per 1000, respectively).

Conclusions

CPIC Level A pharmacogenetic biomarkers are prevalent in Chinese older adults, with over 40% exposed to actionable gene‐drug pairs and 36.5% requiring dose adjustments. These findings highlight the clinical imperative to integrate pharmacogenetic testing into geriatric care, prioritize CYP2C19 and SLCO1B1 testing, and develop region‐specific guidelines to mitigate polypharmacy risks. Policymakers and clinicians should consider targeted implementation strategies to optimize prescribing safety and efficacy in aging populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pharmacogenomic TestingPharmacogeneticsPractice Patterns, Physicians'HumansAgedCross-Sectional StudiesMaleFemaleRetrospective StudiesChinaAged, 80 and overPolypharmacyLiver-Specific Organic Anion Transporter 1BiomarkersCytochrome P-450 CYP2C19Genotype

Stichwörter der Autor:innen

clinical impactgeriatricindividualized medicinepharmacogenetic

Substanzen

Liver-Specific Organic Anion Transporter 1BiomarkersCytochrome P-450 CYP2C19

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual…
  • School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
  • Department of Pharmacy, Peking Union Medical College Hospital, Beijing, China.
  • Department of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Xiaodong Guan, Xiaoyan Nie

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhao, Z., Zhao, Y., Hu, X., Wang, X., Wang, G., Zhang, X., Dong, W., Shi, L., Guan, X., Lu, C. Y., Jin, P., & Nie, X. (2025). Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People. Journal of the American Geriatrics Society, 73(12), 3679-3689. https://doi.org/10.1111/jgs.70126

Vancouver

Zhao Z, Zhao Y, Hu X, Wang X, Wang G, Zhang X, et al. Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People. Journal of the American Geriatrics Society. 2025;73(12):3679-3689. doi:10.1111/jgs.70126

BibTeX
@article{Zhao2025,
  author = {Zhao, Zinan and Zhao, Yuxuan and Hu, Xiaowen and Wang, Xue and Wang, Gengchen and Zhang, Xinyi and Dong, Wenliang and Shi, Luwen and Guan, Xiaodong and Lu, Christine Y and Jin, Pengfei and Nie, Xiaoyan},
  title = {Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People},
  journal = {Journal of the American Geriatrics Society},
  year = {2025},
  volume = {73},
  number = {12},
  pages = {3679--3689},
  doi = {10.1111/jgs.70126}
}
Kostenlos starten →